Edition:
United States

Novartis AG (NVS)

NVS on New York Consolidated

78.96USD
30 Sep 2016
Change (% chg)

$-0.29 (-0.37%)
Prev Close
$79.25
Open
$78.41
Day's High
$79.14
Day's Low
$78.28
Volume
3,635,597
Avg. Vol
1,506,061
52-wk High
$95.11
52-wk Low
$69.89

Summary

Name Age Since Current Position

Joerg Reinhardt

60 2013 Chairman of the Board of Directors

Joseph Jimenez

56 2010 Chief Executive Officer, Member of the Executive Committee

Enrico Vanni

65 2013 Independent Non-Executive Vice Chairman of the Board

Harry Kirsch

50 2013 Chief Financial Officer, Member of the Executive Committee

Felix Ehrat

59 2012 Group General Counsel, Member of the Executive Committee

Steven Baert

41 2014 Head of Human Resources and Member of the Executive Committee

David Epstein

54 2010 Member of the Executive Committee, Division Head, Pharmaceuticals

Mark Fishman

64 2002 Member of the Executive Committee and President of Novartis Institute for BioMedical Research (NIBR)

Richard Francis

47 2014 Member of the Executive Committee and Division Head, Sandoz

Jeffrey George

42 2014 Member of the Executive Committee and Division Head, Alcon.

Andre Wyss

48 2014 Member of the Executive Committee, Global Head, Novartis Business Services and Country President for Switzerland

Charlotte Pamer-Wieser

2011 Corporate Secretary

Nancy Andrews

57 2015 Non-Executive Independent Director

Dimitri Azar

57 2012 Non-Executive Independent Director

Verena Briner

65 2013 Non-Executive Independent Member of the Board

Srikant Datar

62 2003 Non-Executive Independent Director

Ann Fudge

65 2008 Non-Executive Independent Director

Pierre Landolt

69 1996 Non-Executive Independent Director

Charles Sawyers

56 2013 Non-Executive Independent Director

Andreas von Planta

61 2006 Non-Executive Independent Director

William Winters

55 2013 Non-Executive Independent Director

Samir Shah

2013 Global Head Investor Relations

Biographies

Name Description

Joerg Reinhardt

Mr. Joerg Reinhardt, Ph.D. is Chairman of the Board of Directors of Novartis AG since August 2013. He is Chairman of the Chairman's Committee. Dr. Reinhardt previously served as chairman of the board of management and the executive committee of Bayer HealthCare. Prior to that, he served as Chief Operating Officer of Novartis from 2008 to 2010, and as Head of the Vaccines and Diagnostics Division of Novartis from 2006 to 2008. He also served as Chairman of the Board of the Genomics Institute of the Novartis Research Foundation in the United States from 2000 to 2010; as a member of the supervisory board of MorphoSys AG in Germany from 2001 to 2004; and as a member of the board of directors of Lonza Group AG in Switzerland from 2012 to 2013. He is currently a member of the Council of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). Dr. Reinhardt graduated with a Ph.D. in pharmaceutical sciences from Universitaet des Saarlandes, Saarbruecken. He joined Sandoz Pharma Ltd. in 1982 and held various positions including Head of Development. Following the merger that created Novartis in 1996, Dr. Reinhardt became Head of Preclinical Development and Project Management at Novartis, and assumed the position of Head of Pharmaceutical Development in 1999. His leadership, Global and Industry experience include being former chairman of global healthcare company; former Chief Operating Officer of Novartis and former Chairman of Novartis research institution; former board member of biotechnology company; former board member of global supplier for pharmaceutical, healthcare, and life sciences industries; member of global non-profit representing pharmaceutical industry.

Joseph Jimenez

Mr. Joseph S. Jimenez is Chief Executive Officer and Member of the Executive Committee of Novartis AG since February 1, 2010. Prior to that, he served as CEO - Pharmaceuticals Division as of October 2007. In the Company he is responsible for heading the Company's diversified healthcare portfolio of innovative pharmaceuticals, generics, vaccines and diagnostics and consumer health products. Previously, Mr. Jimenez served as Division Head, Novartis Pharmaceuticals. Mr. Jimenez joined Novartis in April 2007 as Division Head, Novartis Consumer Health. Previously, he served as President and Chief Executive Officer (CEO) of the North America business for the H.J. Heinz Company and as President and CEO of Heinz in Europe from 2002 to 2006. Prior to joining Novartis, he was a Non-Executive Director of Astra-Zeneca plc, United Kingdom, from 2002 to 2007. He was also an advisor for the private equity organization Blackstone Group in the United States. Mr. Jimenez is Member of the Board of Directors of Colgate-Palmolive. He graduated with a bachelors degree from Stanford University in 1982 and with a Master of Business Administration (MBA) degree from the University of California, Berkeley, in 1984.

Enrico Vanni

Dr. Enrico Vanni, Ph.D., is Independent Non-Executive Vice Chairman of the Board at Novartis Inc. since February 22, 2013. He was Member of the Board of Directors at Novartis AG since 2011 till February 22, 2013. He qualifies as an Independent Non-Executive Director. He is Member of the Audit and Compliance Committee, and Chairman of the Compensation Committee at the Company. He began his career as a research engineer at International Business Machines Corp. in California, and joined McKinsey & Company in Zurich, Switzerland, in 1980. He managed the Geneva office for McKinsey from 1988 to 2004, and consulted for companies in the pharmaceutical, consumer and finance sectors. He led its European pharmaceutical practice and served as Member of the Partner review committee of the firm prior to his retirement in 2007. Since his retirement as Director of McKinsey & Company in 2007, Dr. Vanni has been an independent consultant. He is currently Member of several Boards of Directors in industries from healthcare to private banking, for nonlisted companies including Eclosion2, Denzler & Partners SA and Banque Privee BCP (Suisse) SA. Dr. Vanni holds an engineering degree in chemistry from Ecole polytechnique federale de Lausanne (the Federal Polytechnic School of Lausanne), Switzerland, a Ph.D. in chemistry from Universite de Lausanne, as well as a Master of Business Administration from INSEAD in Fontainebleau, France.

Harry Kirsch

Mr. Harry Kirsch is Chief Financial Officer and Member of the Executive Committee of Novartis AG since May 1, 2013. Mr. Kirsch joined Novartis in 2003 and previously served as Chief Financial Officer of the Company’s Pharmaceuticals Division. At Novartis, he also served as Chief Financial Officer of Pharma Europe, and as Head of Business Planning & Analysis and Financial Operations for the Pharmaceuticals Division. Mr. Kirsch joined Novartis from Procter & Gamble (P&G) in the United States, where he was CFO of P&G's global pharmaceuticals business. Prior to that, he held finance positions in different categories of P&G's consumer goods business, technical operations, and Global Business Services organization. Mr. Kirsch studied industrial engineering and economics at the Universitaet Karlsruhe in Germany (Diplom Wirtschaftsingenieur).

Felix Ehrat

Dr. Felix R. Ehrat, Ph.D., is Group General Counsel and Member of the Executive Committee of Novartis AG since January 1, 2012. He joined the Company in October 2011 as General Counsel and a permanent attendee of the Executive Committee. Dr. Ehrat is a practitioner of corporate, banking, and mergers and acquisitions law, as well a in corporate governance and arbitration. He started his career as an associate with Baer & Karrer Ltd. in Zurich in 1987, became Partner in 1992, and advanced to Senior Partner (2003 to 2011) and Executive Chairman of the Board (2007 to 2011) of the firm. Dr. Ehrat is Chairman of Globalance Bank AG in Switzerland, and Member of the Board of Liechtensteinische Landesbank AG in Liechtenstein. Previously, Dr. Ehrat was Chairman of Banca del Gottardo, and a Board Member of Julius Baer Holding AG, Austriamicrosystems AG, Charles Voegele Holding AG, and Carlo Gavazzi Holding AG. Mr. Ehrat was admitted to the Zurich bar in 1985 and received his doctorate of law from Universitaet Zuerich (the University of Zurich) in 1990. In 1986, he completed an LL.M. at McGeorge School of Law in the United States. His past memberships and positions include: the International Bar Association, where he was co-chair of the Committee on Corporate and M&A Law from 2007 to 2008; Association Internationale des Jeunes Avocats, where he was president from 1998 to 1999; and the Swiss Arbitration Association, the Zurich Bar Association, and the Swiss Bar Association.

Steven Baert

Mr. Steven Baert has been Head of Human Resources and Member of the Executive Committee of Novartis since February 26, 2014. Mr. Baert joined Novartis in 2006 as Head of Human Resources Global Functions in Switzerland. He also served as Head of Human Resources, United States and Canada, for Novartis Pharmaceuticals Corporation. Prior to joining Novartis, Mr. Baert held positions in human resources for Bristol-Myers Squibb and Unilever.

David Epstein

Mr. David R. Epstein is Member of the Executive Committee and Division Head, Pharmaceuticals at Novartis AG since February 1, 2010. Prior to his current position, Mr. Epstein served as Head of Novartis Oncology since 2000. He led the Molecular Diagnostics unit of the Company since 2008. He is a permanent attendee of the Executive Committee of Novartis. Before joining Novartis, Mr. Epstein was an associate in the Strategy Practice of the consulting firm, Booz Allen & Hamilton. Mr. Epstein joined Sandoz, a predecessor company of Novartis, in 1989, and held various leadership positions of increasing responsibility for the company, including Chief Operating Officer of Novartis Pharmaceuticals Corporation in the United States and Head of Novartis Specialty Medicines. Mr. Epstein graduated with a bachelors degree in pharmacy from Rutgers University College of Pharmacy in 1984, and with a Master of Business Administration in finance and marketing from New York’s Columbia University Graduate School of Business in 1987.

Mark Fishman

Dr. Mark C. Fishman, M.D., is Member of the Executive Committee and President of Novartis Institute for BioMedical Research (NIBR) at Novartis AG since 2002. Before joining Novartis in 2002, Dr. Fishman was Chief of Cardiology and Director of the Cardiovascular Research Center at Massachusetts General Hospital, and Professor of Medicine at Harvard Medical School, both in the United States. Dr. Fishman has worked with national policy and scientific committees, including those of the United States National Institutes of Health (NIH) and the Wellcome Trust. He completed his internal medicine residency, chief residency and cardiology training at Massachusetts General Hospital. Dr. Fishman graduated with a bachelors degree from Yale College in 1972 and a Doctorate of Medicine (M.D.) from Harvard Medical School in 1976. He has been honored with awards and distinguished lectureships, and is Member of the Institute of Medicine of the National Academies (the United States) and a Fellow of the American Academy of Arts and Sciences.

Richard Francis

Mr. Richard Francis is Member of the Executive Committee and Division Head, Sandoz at Novartis AG since May 1, 2014. Most recently, Mr. Francis was the senior vice president of the company’s US commercial organization. Prior to this he served at Biogen Idec, where he held global and country leadership positions. From 1998 to 2001, Mr. Francis was at Sanofi in the United Kingdom, where he held various marketing roles across the company’s urology, analgesics and cardiovascular products. He also has held sales and marketing positions at Lorex Synthelabo and Wyeth. He holds a B.A. in economics from the Manchester Metropolitan University, England.

Jeffrey George

Mr. Jeffrey (Jeff) George is Member of the Executive Committee and Division Head, Alcon at Novartis AG May 1, 2014. He has been Member of the Executive Committee and Division Head, Sandoz since 2010. Before joining Novartis, Mr. George was a Senior Director of Strategy and Business Development at Gap Inc. From 2001 to 2004, he was with McKinsey & Company in San Francisco, United States, where he was an Engagement Manager. Mr. George joined Novartis in the Vaccines and Diagnostics Division in January 2007 as Head of Commercial Operations for Western and Eastern Europe, then advanced to Head of Emerging Markets for the Middle East, Africa, Southeast Asia and CIS at Novartis Pharma. Mr. George graduated in 1999 with a Master’s degree from the Johns Hopkins University School of Advanced International Studies, where he studied international economics and emerging markets political economy. He received a Master of Business Administration from Harvard University in 2001.

Andre Wyss

Mr. Andre Wyss has been Member of the Executive Committee, Global Head, Novartis Business Services and Country President for Switzerland at Novartis AG since July 1, 2014. Previously, he was Global Head of Novartis Business Services (NBS) since May 1, 2014 till July 1, 2014. previously he served as US Country Head and President of Novartis Pharmaceuticals Corporation. Prior to that, he served as Head of the Pharmaceuticals Division Region Asia-Pacific, Middle East and African Countries (AMAC). Before leading AMAC, he served as Group Emerging Markets Head, and as Country President and Head of Pharmaceuticals, Greece. Mr. Wyss received a graduate degree in economics from the School of Economics and Business Administration (HWV).

Charlotte Pamer-Wieser

Ms. Charlotte Pamer-Wieser, Ph.D. serves as Corporate Secretary at Novartis AG since September 2011. In 2004, Ms. Pamer-Wieser started her professional career as associate at Walder Wyss Ltd., in Zurich, Switzerland. From 2007 to 2011, she worked as senior associate for Bär & Karrer Ltd. in Zurich. Her areas of specialization include corporate law, mergers and acquisitions, company reorganizations and banking and finance law. Ms. Pamer-Wieser received a Ph.D. from the Universitaet Basel, Switzerland, and holds a master’s degree in law (LL.M.) from the University of Chicago Law School. In 2002, she was admitted to the Basel bar, and from 2007 to 2010 she was a lecturer at the University of Basel. Ms. Pamer-Wieser has written several articles on corporate law and is a member of the “Association des Jeunes Avocats” (aija) and the American Law and Economics Association.

Nancy Andrews

Ms. Nancy C. Andrews is Non-Executive Independent Director at Novartis Inc. since February 27, 2015. She is a member of the Research & Development Committee at the company. Dr. Andrews is dean of the Duke University School of Medicine and vice chancellor for academic affairs at Duke University in the United States. She is also a professor of pediatrics, pharmacology and cancer biology at Duke. Prior to joining Duke, she was director of the Harvard/MIT M.D.-Ph.D. Program, and dean of basic sciences and graduate studies as well as professor of pediatrics at Harvard Medical School in the US. From 1993 to 2006, Dr. Andrews was a biomedical research investigator at the Howard Hughes Medical Institute, also in the US. Her research is in iron homeostasis and mouse models of human diseases. Dr. Andrews received her Ph.D. in biology from the Massachusetts Institute of Technology in the US and her M.D. from Harvard Medical School. She completed her residency and fellowship trainings in pediatrics and hematology/oncology at Boston Children’s Hospital and the Dana-Farber Cancer Institute, both in the US, and served as an attending physician at Boston Children’s Hospital. Dr. Andrews also served as president of the American Society for Clinical Investigation. Additionally, she was elected as a fellow of the American Association for the Advancement of Science and to membership in the US National Academy of Sciences, the National Academy of Medicine, and the American Academy of Arts and Sciences. She serves on the council of the National Academy of Medicine and on the board of directors of the American Academy of Arts and Sciences.

Dimitri Azar

Dr. Dimitri Azar, M.D., is Non-Executive Independent Director of Novartis AG since February 2012. He qualifies as an independent Non-Executive Director. He is Dean of the College of Medicine and professor of ophthalmology, bioengineering and pharmacology at the University of Illinois at Chicago in the United States, where he formerly was Head of the Department of Ophthalmology and Visual Sciences. He sits on the Board of Trustees of the Chicago Ophthalmological Society and the Association of Research in Vision and Ophthalmology. Dr. Azar is Member of the American Ophthalmological Society and holds committee positions with the American Academy of Ophthalmology. Dr. Azar began his career at the American University Medical Center, Beirut, Lebanon, and completed his fellowship and residency training at the Massachusetts Eye and Ear Infirmary at Harvard Medical School in the United States. Dr. Azar practiced at the Wilmer Ophthalmologic Institute at The Johns Hopkins Hospital School of Medicine, then returned to the Massachusetts Eye and Ear Infirmary as director of the cornea and external disease. He became professor of ophthalmology with tenure at Harvard Medical School in 2003. Dr. Azar holds an Executive Master of Business Administration from the University of Chicago, Booth School of Business.

Verena Briner

Dr. Verena A. Briner, M.D., serves as Non-Executive Independent Member of the Board of Novartis AG since 2013. Dr. Briner is professor of internal medicine at the Universitaet Basel, Switzerland, and chief medical officer and head of the department of medicine at the Lucerne Cantonal Hospital in Switzerland. She is a member of several medical and ethical institutions and commissions, including the board of the Foundation for the Development of Internal Medicine in Europe, the senate of the Swiss Academy of Medical Sciences, and the supervisory group for personalized medicine of the Centre for Technology Assessment TA-SWISS. She also is a member and former president of the Swiss Society of Internal Medicine. Dr. Briner graduated from the Universitaet Basel with an M.D. in 1978, and has a specialized degree in internal medicine and nephrology from the Swiss Medical Association. She has received several prestigious scholarships and scientific grants, including the President’s Grant of the Society of General Internal Medicine in 2011, and is an honorary fellow of the American College of Physicians, the European Federation of Internal Medicine, the Polish Association of Internal Medicine, and the Swiss Society of General Internal Medicine. She was chief medical officer and department head at Swiss hospital; former president of Swiss medical society; member of various medical and ethical institutions and commissions.

Srikant Datar

Dr. Srikant Datar, Ph.D., has been Non-Executive Independent Director of Novartis AG since 2003. He qualifies as Independent Non-Executive Director. He is Chairman of the Audit and Compliance Committee and was Member of the Risk Committee and the Compensation Committee at the Company. Dr. Datar has worked as an accountant and planner in industry, and as a professor at Carnegie Mellon University, Stanford University and Harvard University in the United States. His research interests are in the areas of cost management, measurement of productivity, product development, timebased competition, incentives and performance evaluation. He is the author of a number of scientific publications and has received several academic awards and honors. Dr. Datar has advised and worked with numerous companies in research, development and training. Dr. Datar is Arthur Lowes Dickinson Professor at the Graduate School of Business Administration at Harvard University. He is also Member of the Board of Directors of ICF International Inc. and of Stryker Corp., both in the United States, and of KPIT Cummins Infosystems Ltd., India. He graduated with distinction in mathematics and economics from the University of Bombay, India, in 1973. He is a Chartered Accountant and holds two Masters degrees and a Doctor of Philosophy (Ph.D.) from Stanford University, United States.

Ann Fudge

Ms. Ann M. Fudge has been Non-Executive Independent Director at Novartis AG since February 26, 2008. She is Member of the Risk Committee as well as Corporate Governance and Nomination Committee of the Company. She is former Chairwoman and Chief Executive Officer of Young & Rubicam Brands. Before that, she served as President of the Beverages, Desserts and Post Division of Kraft Foods. Ms. Fudge serves on the Board of Directors of General Electric Co., on the Board of Directors of Unilever, United Kingdom /Netherlands and on the Board of Directors of Infosys, India. She is a trustee of the New York-based Rockefeller Foundation and the Atlanta-based Morehouse College, and Chairman of the United States Programs Advisory Panel of the Bill & Melinda Gates Foundation. Ms. Fudge is further Member of the Harvard University Corporation Committee on Finance. She also sits on the Board of the Council on Foreign Relations. Ms. Fudge received her Bachelors degree from Simmons College and her Masters of Business Administration degree from Harvard University Graduate School of Business in the United States.

Pierre Landolt

Dr. Pierre Landolt, Ph.D., serves as Non-Executive Independent Director at Novartis AG since 1996. He is Member of the Corporate Governance and Nomination Committee at the Company. From 1974 to 1976, he worked for Sandoz Brazil SA. In 1977, he acquired an agricultural estate in the semi-arid Northeast Region of Brazil and, over several years, converted it into a model farm in organic and biodynamic production. Since 1997, Dr. Landolt has been Associate and Chairman of AxialPar Ltda, Brazil, an investment company focused on sustainable development, with investments in fish farming, soybean for human consumption and organic vegetable. In 2000, he co-founded EcoCarbone SA, France, a company active in the design and development of carbon-sequestration processes in Asia, Africa, South America and Europe. In 2007, he co-founded Amazentis SA, Switzerland, a startup company active in the convergence space of medication and nutrition. He is a Member of the Board of Directors of Syngenta AG and a Partner with unlimited liabilities of the Swiss private bank Landolt & Cie. In Brazil, Dr. Landolt serves as President of the Instituto Fazenda Tamandua, the Instituto Estrela de Fomento ao Microcredito, AxialPar Ltda. and Moco Agropecuaria Ltda. In Switzerland, he is Chairman of Emasan AG and Vaucher Manufacture Fleurier SA, Vice Chairman of Parmigiani Fleurier SA, and is on the Board of the Syngenta Foundation for Sustainable Agriculture. He is Member of the Board of EcoCarbone SA, France, and Swiss Amazentis SA. He is also Vice Chairman of the Montreux Jazz Festival Foundation. Dr. Landolt graduated with a Bachelors degree in Law from the University of Paris-Assas.

Charles Sawyers

Dr. Charles L. Sawyers, M.D., has been Non-Executive Independent Director of Novartis AG since 2013. In the United States, Dr. Sawyers is chair of the Human Oncology and Pathogenesis Program at Memorial Sloan-Kettering Cancer Center; professor of medicine and of cell and developmental biology at the Weill Cornell Graduate School of Medical Sciences; and an investigator at the Howard Hughes Medical Institute. He serves on U.S. President Barack Obama’s National Cancer Advisory Board, and is president-elect of the American Association of Cancer Research, and former president of the American Society for Clinical Investigation. He also is a member of the U.S. National Academy of Sciences and Institute of Medicine. Dr. Sawyers received his M.D. from the Johns Hopkins School of Medicine in the United States, and worked at the Jonsson Comprehensive Cancer Center at the University of California, Los Angeles for nearly 18 years before joining Memorial Sloan-Kettering in 2006. He is cancer researcher; and co developed the Novartis cancer drug Gleevec/Glivec, and has received numerous honors and awards, including the Lasker- DeBakey Clinical Medical Research Award in 2009. He was program chair at cancer treatment and research institution; member of U.S. cancer advisory board; president-elect of organization; former president of medical honor society.

Andreas von Planta

Dr. Andreas von Planta, Ph.D., has been Non-Executive Independent Director at Novartis AG since February 28, 2006. He qualifies as an independent Non-Executive Director of the Company. He is Chairman of the Risk Committee, Member of the Audit and Compliance Committee, and the Corporate Governance and Nomination Committee at the Company. He passed his bar examinations in Basel in 1982. Since 1983, he has been working for the law firm Lenz & Staehelin in Geneva, where he became a partner in 1988. His areas of specialization include corporate law, corporate finance, company reorganizations, and mergers and acquisitions. Mr. von Planta is Chairman of the Schweizerische National-Versicherungs-Gesellschaft AG and a Board Member of Holcim Ltd., both in Switzerland. He is also a Board Member of various Swiss subsidiaries of foreign companies and other nonlisted Swiss companies. He is Member of the Board of Editors of the Swiss Review of Business Law and former Chairman of the Geneva Association of Business Law. Mr. von Planta is Chairman of the regulatory board of the SIX Swiss Exchange AG. Mr. von Planta holds Lizentiat des Rechts (lic. iur., LLB) and Doctorote in Philosophy (Ph.D.) degrees from Universitaet Basel, Switzerland, and an Master of Laws (LL.M.) from Columbia University School of Law, New York, United States.

William Winters

Mr. William (Bill) T. Winters has been Non-Executive Independent Director of Novartis AG since 2013. Mr. Winters is chairman and Chief Executive Officer of Renshaw Bay, an alternative asset management and advisory company based in London. He is a former member of the UK Independent Commission on Banking, and served as co-Chief Executive Officer of JPMorgan’s investment banking business from 2003 to 2010. Mr. Winters received his bachelor’s degree from Colgate University and his Masters of Business Administration from the Wharton School at the University of Pennsylvania. He joined JPMorgan in 1983 and held management roles across several market areas and in corporate finance during his time there. Mr. Winters serves on the boards of Colgate University and the International Rescue Committee, both in the United States, and of the Young Vic Theatre and The Print Room, both in London. His leadership and Global experience include chairman and Chief Executive Officer of alternative asset management and advisory company; former co-Chief Executive Officer of investment banking at global financial services firm.

Samir Shah

Basic Compensation

Name Fiscal Year Total

Joerg Reinhardt

3,829,200

Joseph Jimenez

5,414,980

Enrico Vanni

504,357

Harry Kirsch

2,677,160

Felix Ehrat

2,356,020

Steven Baert

1,993,950

David Epstein

5,188,610

Mark Fishman

3,091,360

Richard Francis

3,063,300

Jeffrey George

2,734,580

Andre Wyss

2,121,980

Charlotte Pamer-Wieser

--

Nancy Andrews

275,000

Dimitri Azar

390,000

Verena Briner

334,357

Srikant Datar

480,000

Ann Fudge

390,000

Pierre Landolt

363,492

Charles Sawyers

355,000

Andreas von Planta

454,357

William Winters

325,000

Samir Shah

--
As Of  30 Dec 2015